CrossAssetDataThe Company File
···
NIVF

NewGenIvf Group Limited

NewGenIvf Group Limited is classed by the SEC under Services-Misc Health & Allied Services, NEC (industry code 8090), based in Bangkok, TH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $5 million and a profit of $10 million (its filed statements).

Usage business Services-Misc Health & Allied Services, NEC Bangkok, TH filings since 2023 8 of 9 filed, 1 estimated
Ask the desk about NIVF → Compare NIVF with CCEL → Price chart on TradingView ↗ Full EDGAR file ↗ Watch NIVF →

Sector peers: CCELMGRXVMDBRTX

3.9/10headline grade
vs its business-model standard
3.4/10past 3.7/10present 4.6/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8090, Services-Misc Health & Allied Services, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 3.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.4 out of ten, present 3.7 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 5.5 out of ten. 1 warning event since 2023; the latest 2024-04-30. 55th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.0 out of ten. +3.5% a year over 5 filed years; profitable in 3 of 5. 30th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 1.0 out of ten. Share count grew 383.1% a year. 0% of cash flow returned. Insiders: 0 sales, 4 purchases. 10th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.1 out of ten. ROE 38%: 38¢ of profit per shareholder dollar. Leverage 21%: owes 21¢ per asset dollar. 51st percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 4.3 out of ten. bottom 43% of 10 in its family; net margin 209%. 43rd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 0.6 out of ten. CrossAssetData estimate 0.6/10, confidence 35 of 100 (one part). 6th percentile among 10 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Room to expand (future): 2.9 out of ten. bottom 29% of 10 in its family for room to expand. 29th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 3.5 out of ten. bottom 35% of 10 in its family for growth drivers. 35th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 7.2 out of ten. top 28% of 10 in its family for expectations against reality. 72nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 20-F filed 2026-03-31 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-10-07. Filings on record since 2023. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: IVF Treatment Service 83%, Fertility Referral Services 17%. By geography: Kyrgyzstan 49%, Thailand 36%, Cambodia 13%, United States 1%, China / HK SAR 1%. As tagged in its annual report (Form 20-F, filed 2026-03-31).

Who runs it

Siu, Wing Fung Alfred (Chairman & CEO); Chung, Ho Fai (Chief Financial Officer); Chan, Chung Ho (Chief Financial Officer); Fong, Hei Yue Tina (Chief Marketing Officer); Lau, Tsz Hin Vincent (director); Cheung, Kong Yiu (director); Lam, Chun Tung Patrick (director); Lee, Sze Mun (director); Ching, Chan Florianna Ann Chi Wan (director); Tam, Chun Wa (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-06.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.